The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)

Sheba Medical Center

Status and phase: Enrolling; Phase 4

Conditions: Fragile X Syndrome; Williams Syndrome; Velocardiofacial Syndrome

Treatments: Drug: methylphenidate, fluoxetin, risperidone

Study type: Interventional

Funder types: Other

Identifiers

NCT00768820

SCMCI082455CTIL

Details and patient eligibility

About

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Enrollment: 400 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• chromosomal deletion proven by FISH examination

Exclusion Criteria:

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

400 participants in 1 patient group

1

Experimental group

Treatment:

Drug: methylphenidate, fluoxetin, risperidone